S2Medical AB (publ) (S2M.ST)
- Previous Close
0.0109 - Open
0.0112 - Bid 0.0111 x --
- Ask 0.0115 x --
- Day's Range
0.0105 - 0.0117 - 52 Week Range
0.0055 - 0.0737 - Volume
7,089,748 - Avg. Volume
8,171,611 - Market Cap (intraday)
9.625M - Beta (5Y Monthly) 2.01
- PE Ratio (TTM)
1.14 - EPS (TTM)
0.0100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds in Sweden. It offers Epiprotect 2117, a synthetic allograft/xenograft substitute; Epiprotect Ulcer, a wound dressing consisting of a thin film of biosynthetic cellulose polymer intended to be used as a protective barrier for superficial wounds and deep wounds that have breached the dermis, as well as used as a temporary coverage for deep extensive wounds before transplantation or other surgical intervention. The company also provides washable, durable, waterproof, and self-adhesive bandages under the INSTABIND brand name, as well as NO SMELL, a perfume-free odour remover. The company also distributes Silverlon dressings that deliver a flow of silver ions into the wound; and BIOPAD, an ivory-white soft sponge, and BIOSPRAY, a medication powder form with spray. In addition, it operates the wound healing center under the S2Clinic name. The company was incorporated in 2013 and is headquartered in Linköping, Sweden.
www.s2m.seRecent News: S2M.ST
View MorePerformance Overview: S2M.ST
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: S2M.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: S2M.ST
View MoreValuation Measures
Market Cap
9.20M
Enterprise Value
8.20M
Trailing P/E
1.09
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.62
Price/Book (mrq)
0.78
Enterprise Value/Revenue
0.55
Enterprise Value/EBITDA
1.20
Financial Highlights
Profitability and Income Statement
Profit Margin
38.72%
Return on Assets (ttm)
18.33%
Return on Equity (ttm)
85.75%
Revenue (ttm)
14.91M
Net Income Avi to Common (ttm)
5.77M
Diluted EPS (ttm)
0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
1M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.02M